Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma

NCT04051606 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Glioblastoma

Interventions

DRUG: Regorafenib

Sponsor

Case Comprehensive Cancer Center